Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2213002 | 1.00 | TTR (0.54) | TTRENPP2APPPTPN1CA12 | |
| SCHEMBL29445626 | 1.00 | TTR (0.54) | TTRENPP2APPPTPN1CA12 | |
| SCHEMBL69618 | 0.85 | TTR (0.66) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL2561485 | 0.84 | TTR (0.57) | TTRENPP2CA12CA1CA2 | |
| SCHEMBL2561487 | 0.84 | TTR (0.57) | TTRENPP2CA12CA1CA2 | |
| SCHEMBL15985448 | 0.82 | GLA (0.56) | TTRENPP2APPFDPSTRPV1 | |
| SCHEMBL30098502 | 0.81 | KMT2A (0.58) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL7660046 | 0.81 | KMT2A (0.58) | TTRAPPPTPN1CA12CA1 | |
| Ethane SCHEMBL3344169 | 0.81 | NPSR1 (0.56) | TTRENPP2APPPTPN1CA12 | |
| SCHEMBL1431912 | 0.81 | KMT2A (0.58) | TTRAPPPTPN1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114105976-A | Selective ROCK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-3151833-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | Thomas Helledays Stiftelse För Medicinsk Forskning (SE) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015187089-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2015-12-10 | — | — | WO | disclosed |
| EP-2925744-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | Thomas Helledays Stiftelse För Medicinsk Forskning (SE) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014084778-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2014-06-05 | — | — | WO | disclosed |
| US-8318723-B2 | Pyrazine compounds, their use and methods of preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| EP-2061762-B1 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-20100210627-A1 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | disclosed |
| EP-2061762-A2 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | Boehringer Ingelheim International GmbH (DE) | 2009-05-27 | — | — | EP | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008022164-A2 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | WO | disclosed |
| EP-1773337-A2 | MODULATORS OF NUCLEAR RECEPTORS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006025979-A2 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | NR1H2, NR0B1, NR1H3 | TTR 3647/4885ENPP2 1282/4885APP 4422/4885 |
| US-20100210627-A1 | PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION | CDK2, PIM1, CCNK | TTR 2331/4885ENPP2 1404/4885APP 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.